Oramed Pharmaceuticals (XTAE:ORMP) E10: ₪ (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:ORMP Oramed Pharmaceuticals Inc XTAE:ORMP
26 GF Score
Price ₪14.19
! 4 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals E10?

Oramed Pharmaceuticals XTAE:ORMP 26 E10 is ₪ as of Jun. 2026. GuruFocus rates XTAE:ORMP with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was ₪5.442. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 12.80% per year. During the past 5 years, the average E10 Growth Rate was 1.90% per year. During the past 10 years, the average E10 Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Oramed Pharmaceuticals was 12.80% per year. The lowest was -8.30% per year. And the median was -2.65% per year.

As of today (2026-09-21), Oramed Pharmaceuticals's current stock price is ₪14.19. Oramed Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 was . Oramed Pharmaceuticals's Shiller PE Ratio of today is .


Oramed Pharmaceuticals  (XTAE:ORMP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oramed Pharmaceuticals E10 Related Terms


Oramed Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals E10 Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

XTAE:ORMP vs IMUX, ABOS, ANTX: E10 Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Shiller PE Ratio falls into.


XTAE:ORMP
26GF Score
Oramed Pharmaceuticals Inc XTAE:ORMP
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oramed Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.4424/333.9520*333.9520
=5.442

Current CPI (Jun. 2026) = 333.9520.

Oramed Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201605 -0.572 240.229 -0.796
201608 -1.381 240.849 -1.915
201611 -0.762 241.353 -1.054
201702 -0.911 243.603 -1.248
201705 -0.544 244.733 -0.743
201708 -0.712 245.519 -0.969
201711 -0.634 246.669 -0.858
201802 -0.695 248.991 -0.932
201805 -1.061 251.588 -1.408
201808 -0.655 252.146 -0.867
201811 -0.900 252.038 -1.193
201902 -0.782 252.776 -1.033
201905 -0.840 256.092 -1.095
201908 -0.466 256.558 -0.606
201911 -0.511 257.208 -0.663
202002 -0.716 258.678 -0.924
202005 -0.350 256.394 -0.456
202008 -0.434 259.918 -0.557
202011 -0.795 260.229 -1.021
202102 -0.555 263.014 -0.704
202105 -0.571 269.195 -0.709
202108 -0.680 273.567 -0.830
202203 -0.862 287.504 -1.001
202206 -0.908 296.311 -1.023
202209 -0.614 296.808 -0.691
202212 -0.756 296.797 -0.850
202303 -0.300 301.836 -0.332
202306 -0.108 305.109 -0.119
202309 -0.298 307.789 -0.323
202312 1.262 306.746 1.374
202403 0.135 312.332 0.145
202406 0.825 314.175 0.877
202409 -1.781 315.301 -1.887
202412 -0.945 315.605 -1.000
202503 -0.670 319.799 -0.699
202506 1.117 322.561 1.156
202509 3.804 324.800 3.911
202512 0.740 324.054 0.762
202603 2.847 330.213 2.879
202606 5.442 333.952 5.442

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₪ mean?
Oramed Pharmaceuticals (XTAE:ORMP) has a E10 of ₪ as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' E10 too high?
Oramed Pharmaceuticals' current E10 is ₪. Overall, Oramed Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' E10 compare to IMUX and ABOS?
Oramed Pharmaceuticals' E10 of ₪ can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current E10 is ₪. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (XTAE:ORMP) has a current E10 of ₪. The current E10 is ₪. Oramed Pharmaceuticals' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Oramed Pharmaceuticals (XTAE:ORMP), the current E10 is ₪ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Other Exchanges ORMP:USAOJU1:Germany
Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
26GF Score

Get the complete analysis for XTAE:ORMP

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪14.19
Price